by Rod Raynovich | Apr 4, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Cubist settles with TEVA on generic Cubicin. Cubist was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $22. Teva gets right to generic daptomycin MRSA product on 6/24/18 and admits Cubist patents are valid. Cubist Pharmaceuticals Settles CUBICIN...
by Rod Raynovich | Apr 4, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Platform Technologies Are In Demand: M&A Driver Intact Exact Sciences (EXAS $7.50) continued to run today up 3% and 1.3 pts in five days on no apparent news except presentations at recent investment conferences. The Company is developing a molecular diagnostic...
by Rod Raynovich | Mar 31, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biopharmaceutical stocks caught bids today (in a weak technology market) after yesterday’s M&A spiked rally. Large cap leaders in the NASDAQ-100 were up: Biogen(BIIB) up 1.63%, Celgene (CELG) up 1.6% and Gilead (GILD) up 0.68%. Major ETF’s-IBB FBT XBI-...
by Rod Raynovich | Mar 30, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Optimer soars 11% to $13.13 on presentation of Shea Data and preliminary FDA review: Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients – Yahoo! Finance Optimer...
by Rod Raynovich | Mar 30, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biopharmaceutical Stocks Ignited By M&A Potential M&A has been a key driver for investing in biotech stocks as need for product pipeline and technologies grows. The drug development process is slow and synergies can be found faster by buying companies on the...
by Rod Raynovich | Mar 29, 2011 | 2024-25 Life Science Portfolios, BIOgraph
As has been the pattern lately biotech sector rallies coincide with NASDAQ with the NAZ (2753) up 20.2 or 0.81% . The mid caps are the sweet spot in the market with as our mid-cap index of 33 biotechs are almost all green with the average up 1.57%. 14 of the stocks...
by Rod Raynovich | Mar 29, 2011 | 2024-25 Life Science Portfolios, BIOgraph
In January we reported from the JPMorgan Healthcare Conference regarding convergence of communications and medical technologies. Two trends mentioned were use of cloud computing and connectivity in medicine. Here is a brief update: Abbott (ABT $48) announced today...
by Rod Raynovich | Mar 24, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Biotech rally day with speculative news: ASCO,M&A,and Clinical News. Biotech stocks were green across the board with our mid-cap index of 33 stocks up 1%. ETF’s were strong: FBT up 1.3%, IBB up 1.3% and XBI up 1.45%. The NAZ is up 1.11%. Some notable winners...
by Rod Raynovich | Mar 23, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Good news boosted many biotech stocks today as the XOMA clinical trial failure of yet another diabetes drug did not scare away investors. Although the major ETF’s were barely up, there were a lot of individual stock winners. Within the Rayno Life Science...
by Rod Raynovich | Mar 18, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Quest Diagnostics said today it would buy the diagnostics company Celera (CRA $8.10) for $671M.Celera business momentum had stalled in 2010 with Q4 Revenue down 11% at $34.9M with Net Income at 3 cents a share down from 4 cents a share in Q4 2009. Results from...
